These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Ozes ON; Akca H; Mayo LD; Gustin JA; Maehama T; Dixon JE; Donner DB Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4640-5. PubMed ID: 11287630 [TBL] [Abstract][Full Text] [Related]
3. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway. Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867 [TBL] [Abstract][Full Text] [Related]
4. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. DeGraffenried LA; Fulcher L; Friedrichs WE; Grünwald V; Ray RB; Hidalgo M Ann Oncol; 2004 Oct; 15(10):1510-6. PubMed ID: 15367412 [TBL] [Abstract][Full Text] [Related]
5. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. She QB; Solit D; Basso A; Moasser MM Clin Cancer Res; 2003 Oct; 9(12):4340-6. PubMed ID: 14555504 [TBL] [Abstract][Full Text] [Related]
6. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Li DM; Sun H Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15406-11. PubMed ID: 9860981 [TBL] [Abstract][Full Text] [Related]
7. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Weng LP; Smith WM; Dahia PL; Ziebold U; Gil E; Lees JA; Eng C Cancer Res; 1999 Nov; 59(22):5808-14. PubMed ID: 10582703 [TBL] [Abstract][Full Text] [Related]
8. 5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells. Taylor V; Wong M; Brandts C; Reilly L; Dean NM; Cowsert LM; Moodie S; Stokoe D Mol Cell Biol; 2000 Sep; 20(18):6860-71. PubMed ID: 10958682 [TBL] [Abstract][Full Text] [Related]
9. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120 [TBL] [Abstract][Full Text] [Related]
10. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779 [TBL] [Abstract][Full Text] [Related]
11. Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells. Yi HK; Kim SY; Hwang PH; Kim CY; Yang DH; Oh Y; Lee DY Biochem Biophys Res Commun; 2005 May; 330(3):760-7. PubMed ID: 15809062 [TBL] [Abstract][Full Text] [Related]
12. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. Blancher C; Moore JW; Robertson N; Harris AL Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776 [TBL] [Abstract][Full Text] [Related]
14. PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Weng LP; Smith WM; Brown JL; Eng C Hum Mol Genet; 2001 Mar; 10(6):605-16. PubMed ID: 11230180 [TBL] [Abstract][Full Text] [Related]
15. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650 [TBL] [Abstract][Full Text] [Related]
16. Overexpression of the Shb SH2 domain-protein in insulin-producing cells leads to altered signaling through the IRS-1 and IRS-2 proteins. Welsh N; Makeeva N; Welsh M Mol Med; 2002 Nov; 8(11):695-704. PubMed ID: 12520086 [TBL] [Abstract][Full Text] [Related]
17. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. Campbell RA; Bhat-Nakshatri P; Patel NM; Constantinidou D; Ali S; Nakshatri H J Biol Chem; 2001 Mar; 276(13):9817-24. PubMed ID: 11139588 [TBL] [Abstract][Full Text] [Related]
18. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Paramio JM; Navarro M; Segrelles C; Gómez-Casero E; Jorcano JL Oncogene; 1999 Dec; 18(52):7462-8. PubMed ID: 10602505 [TBL] [Abstract][Full Text] [Related]
19. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. Nakamura JL; Karlsson A; Arvold ND; Gottschalk AR; Pieper RO; Stokoe D; Haas-Kogan DA J Neurooncol; 2005 Feb; 71(3):215-22. PubMed ID: 15735908 [TBL] [Abstract][Full Text] [Related]